In the 1990s, the pharmaceutical industry developed selective COX-2 inhibitors (coxibs) as alternatives to conventional nonsteroidal anti-inflammatory drugs (NSAIDs), with the expectation of similar analgetic and anti-inflammatory efficacy but a reduced risk of adverse gastrointestinal (GI) effects...
Keywords: Cyclooxygenase 2 inhibitors, anti-inflammatory agents, non-steroidal, cardiovascular diseases, gastrointestinal diseases, legislation, Drug
10/2006 | Thrombosis and Haemostasis, Schattauer